• Journal of radiological science and technology
• /
• v.41 no.1
• /
• pp.47-51
• /
• 2018

To evaluate the applicability of osteoporosis management by statistical analysis of the correlation between bone mineral density (BMD) changes after menopause by dividing the T-score of bone mineral density measured by dual energy X-ray absorptiometry do. Between January 1, 2016 and July 31, 2017, women who visited the medical center of W Medical Center were enrolled in this study. The postmenopausal period was divided into 5 groups, There were 18 patients within 5 years, 44 patients in 6~10 years, 134 patients in 11~15 years, 109 patients in 16~20 years and 21 patients in 21 years or older. And postmenopausal women. Bone mineral density (BMD) of the lumbar spine and femur was measured using a dual energy X-ray absorptiometry. The lowest value among lumbar spine 1, 2, 3 and 4 and the lowest value among the femoral neck, greater trochanter, total femur, and ward Values were measured. The statistical significance was analyzed by using bivariate correlation coefficient method and one - way ANOVA. In 326 patients who underwent BMD, the correlation between bone mineral density and postmenopausal BMD showed a negative correlation (-.159, p<.01) with BMD of femur and BMD of lumbar spine The correlation between the menopausal period and negative (-.208, p<.01) was shown. There was a significant difference (p<.012) between the postmenopausal femur bone density and the mean value of the lumbar spine BMD (p<.000). The relationship between bone mineral density (BMD) and postmenopausal women's postmenopausal status can be estimated by estimating the bone mineral density and using it as a basic data for osteoporosis management.

• Journal of Yeungnam Medical Science
• /
• v.25 no.1
• /
• pp.19-30
• /
• 2008

Osteoporosis, a disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and fracture risk, is a major public health problem. The diagnostic methods for osteoporosis include simple radiography, bone scan, DXA (Dual energy X-ray Absortiometry) and biochemical markers of bone turnover. Optimal treatment and prevention of osteoporosis require modification of risk factors, particularly smoking cessation, adequate physical activity, and attention to diet, in addition to pharmacologic intervention. The estrogens and raloxifene both prevent bone loss in postmenopausal women, and the estrogens probably also decrease the risk of first fracture. There is good evidence that raloxifene prevents further fractures in postmenopausal women who already have had fractures and some evidence that estrogen does as well. Bisphosphonate prevents bone loss and reduces fractures in healthy and osteoporotic postmenopausal women and in osteoporotic men as well. Risedronate is more potent and has fewer side effects than alendronate and reduces the incidence of fractures in osteoporotic women. Calcitonin increases bone mineral density in early postmenopausal women and men with idiopathic osteoporosis, and also reduces the risk of new fractures in osteoporotic women. All of the agents discussed above prevent bone resorption, whereas teriparatide and strontium increase bone formation and are effective in the treatment of osteoporotic women and men. New avenues for targeting osteoporosis will emerge as our knowledge of the regulatory mechanisms of bone remodeling increases, although issues of tissue specificity may remain to be addressed.